Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
7. NuVasive CEO Lukianov looks back, ahead
NuVasive chairman & CEO Alex Lukianov touts expectation-shattering preliminary figures for the company’s 2012 sales and talks about integration and globalization as important drivers for the year ahead.
6. Stryker focuses on expanding foreign sales
Medical device giant Stryker is looking to boost its non-U.S. sales figures with an overhaul of its European business and a growing focus on emerging markets.
5. Zimmer: We’re not pushing the device tax down the line
Orthopedic giant Zimmer Holdings won’t push the cost of the medical device tax down the line to its distributors, according to CEO David Dvorak.
4. Interview: Medtronic CEO Ishrak on the road ahead
Medtronic CEO Omar Ishrak reviews his first full year at the helm of the medical device company for MassDevice.com and outlines his goals for 2013.
3. Mahoney: Too much CEO turnover at Boston Scientific
New Boston Scientific CEO Michael Mahoney is in it for the long haul, he tells investors at the J.P. Morgan Healthcare conference.
2. St. Jude defends Durata amid FDA warning at manufacturing facility
St. Jude Medical CEO Daniel Starks says the FDA’s warnings of manufacturing deficiencies at a California plant are unrelated to the safety and reliability of the Durata defibrillator leads that are made there.
1. Can Boston Scientific capitalize on St. Jude’s challenges?
Boston Scientific CFO Jeffrey Capello says the medical device giant is looking to capitalize on the reliability of its ICD leads, especially in light of the "challenges" faced by an ICD competitor.